The role of renal prostaglandin E and kallikrein in pathogenesis of essential hypertension. 1979

K Abe, and M Yasujima, and Y Sakurai, and S Chiba, and T Itoh, and Y Imai, and M Sato, and T Haruyama, and K Omata, and T Goto, and K Sato, and M Hiwatari, and Y Otsuka, and K Yoshinaga

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D007610 Kallikreins Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77). Kallikrein,Kininogenase,Callicrein,Dilminal,Kallidinogenase,Kalliginogenase,Kallikrein A,Kallikrein B',Kallikrein Light Chain,Kinin-Forming Enzyme,Padutin,alpha-Kallikrein,beta-Kallikrein,beta-Kallikrein B,Enzyme, Kinin-Forming,Kinin Forming Enzyme,Light Chain, Kallikrein,alpha Kallikrein,beta Kallikrein,beta Kallikrein B
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011187 Posture The position or physical attitude of the body. Postures
D011188 Potassium An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D011458 Prostaglandins E (11 alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid (PGE(1)); (5Z,11 alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid (PGE(2)); and (5Z,11 alpha,13E,15S,17Z)-11,15-dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid (PGE(3)). Three of the six naturally occurring prostaglandins. They are considered primary in that no one is derived from another in living organisms. Originally isolated from sheep seminal fluid and vesicles, they are found in many organs and tissues and play a major role in mediating various physiological activities. PGE
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive

Related Publications

K Abe, and M Yasujima, and Y Sakurai, and S Chiba, and T Itoh, and Y Imai, and M Sato, and T Haruyama, and K Omata, and T Goto, and K Sato, and M Hiwatari, and Y Otsuka, and K Yoshinaga
January 1987, Agents and actions. Supplements,
K Abe, and M Yasujima, and Y Sakurai, and S Chiba, and T Itoh, and Y Imai, and M Sato, and T Haruyama, and K Omata, and T Goto, and K Sato, and M Hiwatari, and Y Otsuka, and K Yoshinaga
January 1980, Advances in prostaglandin and thromboxane research,
K Abe, and M Yasujima, and Y Sakurai, and S Chiba, and T Itoh, and Y Imai, and M Sato, and T Haruyama, and K Omata, and T Goto, and K Sato, and M Hiwatari, and Y Otsuka, and K Yoshinaga
October 1979, Nihon rinsho. Japanese journal of clinical medicine,
K Abe, and M Yasujima, and Y Sakurai, and S Chiba, and T Itoh, and Y Imai, and M Sato, and T Haruyama, and K Omata, and T Goto, and K Sato, and M Hiwatari, and Y Otsuka, and K Yoshinaga
March 1980, Polskie Archiwum Medycyny Wewnetrznej,
K Abe, and M Yasujima, and Y Sakurai, and S Chiba, and T Itoh, and Y Imai, and M Sato, and T Haruyama, and K Omata, and T Goto, and K Sato, and M Hiwatari, and Y Otsuka, and K Yoshinaga
January 1987, International journal of clinical pharmacology, therapy, and toxicology,
K Abe, and M Yasujima, and Y Sakurai, and S Chiba, and T Itoh, and Y Imai, and M Sato, and T Haruyama, and K Omata, and T Goto, and K Sato, and M Hiwatari, and Y Otsuka, and K Yoshinaga
July 1984, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
K Abe, and M Yasujima, and Y Sakurai, and S Chiba, and T Itoh, and Y Imai, and M Sato, and T Haruyama, and K Omata, and T Goto, and K Sato, and M Hiwatari, and Y Otsuka, and K Yoshinaga
December 1982, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
K Abe, and M Yasujima, and Y Sakurai, and S Chiba, and T Itoh, and Y Imai, and M Sato, and T Haruyama, and K Omata, and T Goto, and K Sato, and M Hiwatari, and Y Otsuka, and K Yoshinaga
June 1981, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
K Abe, and M Yasujima, and Y Sakurai, and S Chiba, and T Itoh, and Y Imai, and M Sato, and T Haruyama, and K Omata, and T Goto, and K Sato, and M Hiwatari, and Y Otsuka, and K Yoshinaga
April 1995, Journal of cardiovascular risk,
K Abe, and M Yasujima, and Y Sakurai, and S Chiba, and T Itoh, and Y Imai, and M Sato, and T Haruyama, and K Omata, and T Goto, and K Sato, and M Hiwatari, and Y Otsuka, and K Yoshinaga
January 1981, Physiologie (Bucarest),
Copied contents to your clipboard!